News
TCBPW
0.0218
+10.10%
0.0020
Weekly Report: what happened at TCBPW last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at TCBPW last week (0415-0419)?
Weekly Report · 04/22 12:38
Weekly Report: what happened at TCBPW last week (0408-0412)?
Weekly Report · 04/15 12:28
Weekly Report: what happened at TCBPW last week (0401-0405)?
Weekly Report · 04/08 12:34
Weekly Report: what happened at TCBPW last week (0325-0329)?
Weekly Report · 04/01 12:29
Weekly Report: what happened at TCBPW last week (0318-0322)?
Weekly Report · 03/25 12:34
Weekly Report: what happened at TCBPW last week (0311-0315)?
Weekly Report · 03/18 12:32
Weekly Report: what happened at TCBPW last week (0304-0308)?
Weekly Report · 03/11 12:26
Weekly Report: what happened at TCBPW last week (0226-0301)?
Weekly Report · 03/04 12:31
Weekly Report: what happened at TCBPW last week (0219-0223)?
Weekly Report · 02/26 12:52
Weekly Report: what happened at TCBPW last week (0212-0216)?
Weekly Report · 02/19 12:54
TC BIOPHARM HOLDINGS PLC: Current report
Press release · 02/15 08:59
Weekly Report: what happened at TCBPW last week (0205-0209)?
Weekly Report · 02/12 12:38
Weekly Report: what happened at TCBPW last week (0129-0202)?
Weekly Report · 02/05 12:52
Weekly Report: what happened at TCBPW last week (0122-0126)?
Weekly Report · 01/29 12:32
Weekly Report: what happened at TCBPW last week (0115-0119)?
Weekly Report · 01/22 12:39
Weekly Report: what happened at TCBPW last week (0108-0112)?
Weekly Report · 01/15 12:33
Weekly Report: what happened at TCBPW last week (0101-0105)?
Weekly Report · 01/08 12:39
TC BIOPHARM HOLDINGS PLC: Current report
Press release · 01/04 16:13
Weekly Report: what happened at TCBPW last week (1225-1229)?
Weekly Report · 01/01 12:31
More
Webull provides a variety of real-time TCBPW stock news. You can receive the latest news about TC BIOPHARM HOLDINGS PLC through multiple platforms. This information may help you make smarter investment decisions.
About TCBPW
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.